The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach f...

Full description

Bibliographic Details
Main Authors: Irina V. Poddubnaya, Tatyana E. Bialik, Natalya N. Glonina, Olga B. Kalashnikova, Kamil D. Kaplanov, Valery A. Lapin, Nadezhda V. Medvedeva, Natalya B. Mikhailova, Tatyana N. Moiseeva, Evgeniy A. Nikitin, Tatyana I. Pospelova, Elena A. Stadnik
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-05-01
Series:Современная онкология
Subjects:
chronic lymphocytic leukemia
bruton tyrosine kinase inhibitors
immunochemotherapy
targeted therapy
ibrutinib
acalabrutinib
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/34009/21719

Similar Items